Moderna, Inc. (NASDAQ:MRNA) Insider Juan Andres Sells 2,000 Shares

Moderna, Inc. (NASDAQ:MRNAGet Rating) insider Juan Andres sold 2,000 shares of the company’s stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $167.99, for a total value of $335,980.00. Following the completion of the transaction, the insider now directly owns 10,367 shares in the company, valued at approximately $1,741,552.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Juan Andres also recently made the following trade(s):

  • On Wednesday, July 27th, Juan Andres sold 2,000 shares of Moderna stock. The shares were sold at an average price of $161.00, for a total transaction of $322,000.00.
  • On Wednesday, July 20th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $167.00, for a total transaction of $334,000.00.
  • On Wednesday, July 13th, Juan Andres sold 2,000 shares of Moderna stock. The shares were sold at an average price of $168.88, for a total transaction of $337,760.00.
  • On Wednesday, July 6th, Juan Andres sold 2,000 shares of Moderna stock. The shares were sold at an average price of $154.85, for a total transaction of $309,700.00.
  • On Friday, July 1st, Juan Andres sold 6,000 shares of Moderna stock. The stock was sold at an average price of $150.00, for a total transaction of $900,000.00.
  • On Tuesday, May 31st, Juan Andres sold 749 shares of Moderna stock. The shares were sold at an average price of $145.40, for a total value of $108,904.60.
  • On Tuesday, May 10th, Juan Andres sold 195 shares of Moderna stock. The shares were sold at an average price of $133.71, for a total value of $26,073.45.

Moderna Stock Down 3.8 %

MRNA stock opened at $186.84 on Friday. Moderna, Inc. has a 1-year low of $115.61 and a 1-year high of $497.49. The firm has a market cap of $74.32 billion, a price-to-earnings ratio of 5.69, a PEG ratio of 1.09 and a beta of 1.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.99 and a quick ratio of 1.56. The firm has a fifty day moving average price of $152.33 and a two-hundred day moving average price of $152.85.

Moderna (NASDAQ:MRNAGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, topping the consensus estimate of $4.73 by $0.51. The firm had revenue of $4.73 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Moderna had a net margin of 61.12% and a return on equity of 94.76%. Moderna’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business earned $6.46 earnings per share. Research analysts predict that Moderna, Inc. will post 27.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MRNA. Piper Sandler decreased their price target on Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a research report on Tuesday, May 17th. Morgan Stanley dropped their price target on Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a research report on Thursday. Finally, SVB Leerink upped their price objective on Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a research note on Monday, August 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $226.92.

Institutional Investors Weigh In On Moderna

A number of large investors have recently added to or reduced their stakes in MRNA. Vestmark Advisory Solutions Inc. raised its stake in shares of Moderna by 108.5% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 1,084 shares of the company’s stock valued at $275,000 after purchasing an additional 564 shares in the last quarter. D.A. Davidson & CO. increased its stake in shares of Moderna by 28.9% in the fourth quarter. D.A. Davidson & CO. now owns 7,143 shares of the company’s stock valued at $1,814,000 after buying an additional 1,600 shares in the last quarter. CWM LLC bought a new position in Moderna in the fourth quarter valued at about $810,000. Capital Investment Advisory Services LLC boosted its holdings in Moderna by 38.0% in the fourth quarter. Capital Investment Advisory Services LLC now owns 998 shares of the company’s stock valued at $253,000 after acquiring an additional 275 shares during the last quarter. Finally, AGF Investments Inc. boosted its holdings in Moderna by 89.4% during the fourth quarter. AGF Investments Inc. now owns 2,826 shares of the company’s stock worth $718,000 after buying an additional 1,334 shares during the last quarter. Institutional investors own 61.20% of the company’s stock.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Recommended Stories

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.